The Effect of Reparixin on Survival in Patients at High Risk for In-hospital Mortality: a Meta-analysis of Randomized Trials

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 12

PMID 35958623

Authors

Giovanni Landoni

Alberto Zangrillo

Gioia Piersanti

Tommaso Scquizzato

Lorenzo Piemonti

Affiliations

Soon will be listed here.

Abstract

Introduction: A great number of anti-inflammatory drugs have been suggested in the treatment of SARS-CoV-2 infection. Reparixin, a non-competitive allosteric inhibitor of the CXCL8 (IL-8) receptors C-X-C chemokine receptor type 1 (CXCR1) and C-X-C chemokine receptor type 2 (CXCR2), has already been tried out as a treatment in different critical settings. Due to the contrasting existing literature, we decided to perform the present meta-analysis of randomized controlled trials (RCTs) to investigate the effect of the use of reparixin on survival in patients at high risk for in-hospital mortality.

Methods: We created a search strategy to include any human RCTs performed with reparixin utilization in patients at high risk for in-hospital mortality, excluding oncological patients. Two trained, independent authors searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) for appropriate studies. Furthermore, references of review articles and included RCTs were screened to identify more studies. No language restrictions were enforced. To assess the risk of bias of included trials, the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) was used.

Results: Overall, six studies were included and involved 406 patients (220 received reparixin and 186 received the comparator). The all-cause mortality in the reparixin group was significantly lower than that in the control group [5/220 (2.3%) in the reparixin group vs. 12/186 (6.5%) in the control group, odds ratio = 0.33 (95% confidence interval 0.12 to 0.96), -value for effect 0.04, for heterogeneity 0.20, = 36%]. In addition, no difference in the rate of pneumonia, sepsis, or non-serious infections was shown between the two groups.

Conclusion: Our meta-analysis of randomized trials suggests that short-term inhibition of CXCL8 activity improved survival in patients at high risk for in-hospital mortality without increasing the risk of infection.

Meta-analysis Registration: PROSPERO, identifier CRD42021254467.

Citing Articles

CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.

Deschamps P, Wacheux M, Gosseye A, Morabito M, Pages A, Lyne A J Clin Invest. 2024; 134(22).

PMID: 39545419 PMC: 11563679. DOI: 10.1172/JCI180738.

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study.

Piemonti L, Landoni G, Voza A, Puoti M, Gentile I, Coppola N Infect Dis Ther. 2023; 12(10):2437-2456.

PMID: 37798468 PMC: 10600076. DOI: 10.1007/s40121-023-00871-5.

Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.

Shpakov A Int J Mol Sci. 2023; 24(7).

PMID: 37047169 PMC: 10094638. DOI: 10.3390/ijms24076187.

References

Gregoire M, Uhel F, Lesouhaitier M, Gacouin A, Guirriec M, Mourcin F . Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS. Eur Respir J. 2018; 52(2). DOI: 10.1183/13993003.02590-2017. View

Hu Y, Huang K, Ji Z, Wang S, Bai M, Pan S . High neutrophil-to-lymphocyte ratio is associated with poor clinical outcome in patients with critically ill stroke. Minerva Anestesiol. 2020; 86(9):939-947. DOI: 10.23736/S0375-9393.20.14310-4. View

Hemmat N, Derakhshani A, Baghi H, Silvestris N, Baradaran B, De Summa S . Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study. Front Genet. 2020; 11:641. PMC: 7296827. DOI: 10.3389/fgene.2020.00641. View

Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifiro G . Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front Pharmacol. 2020; 11:588654. PMC: 7677570. DOI: 10.3389/fphar.2020.588654. View

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A . Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):761-770. PMC: 7170362. DOI: 10.1080/22221751.2020.1747363. View

de Oliveira S, Rosowski E, Huttenlocher A . Neutrophil migration in infection and wound repair: going forward in reverse. Nat Rev Immunol. 2016; 16(6):378-91. PMC: 5367630. DOI: 10.1038/nri.2016.49. View

Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C . Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020; 18(1):206. PMC: 7237880. DOI: 10.1186/s12967-020-02374-0. View

Miao M, De Clercq E, Li G . Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol. 2020; 16(1):11-30. DOI: 10.1080/17425255.2020.1711884. View

Miller E, Cohen A, Nagao S, Griffith D, Maunder R, Martin T . Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis. 1992; 146(2):427-32. DOI: 10.1164/ajrccm/146.2.427. View

10.

Sadik C, Luster A . Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. J Leukoc Biol. 2011; 91(2):207-15. PMC: 3290425. DOI: 10.1189/jlb.0811402. View

11.

Yan L, Hu Z . Red Blood Cell Distribution Width, Neutrophil-to-Lymphocyte Ratio, and In-Hospital Mortality in Dyspneic Patients Admitted to the Emergency Department. Dis Markers. 2020; 2020:8839506. PMC: 7321522. DOI: 10.1155/2020/8839506. View

12.

Mikacenic C, Moore R, Dmyterko V, West T, Altemeier W, Liles W . Neutrophil extracellular traps (NETs) are increased in the alveolar spaces of patients with ventilator-associated pneumonia. Crit Care. 2018; 22(1):358. PMC: 6307268. DOI: 10.1186/s13054-018-2290-8. View

13.

Li W, Ai X, Ni Y, Ye Z, Liang Z . The Association Between the Neutrophil-to-Lymphocyte Ratio and Mortality in Patients With Acute Respiratory Distress Syndrome: A Retrospective Cohort Study. Shock. 2018; 51(2):161-167. DOI: 10.1097/SHK.0000000000001136. View

14.

Fan L, Jun Wang Y, Nan C, He Chen Y, Su H . Neutrophil-lymphocyte ratio is associated with all-cause mortality among critically ill patients with acute kidney injury. Clin Chim Acta. 2018; 490:207-213. DOI: 10.1016/j.cca.2018.09.014. View

15.

Middleton E, He X, Denorme F, Campbell R, Ng D, Salvatore S . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020; 136(10):1169-1179. PMC: 7472714. DOI: 10.1182/blood.2020007008. View

16.

Li H, Zhang J, Fang C, Zhao X, Qian B, Sun Y . The prognostic value of IL-8 for the death of severe or critical patients with COVID-19. Medicine (Baltimore). 2021; 100(11):e23656. PMC: 7982189. DOI: 10.1097/MD.0000000000023656. View

17.

Flori H, Sapru A, Quasney M, Gildengorin G, Curley M, Matthay M . A prospective investigation of interleukin-8 levels in pediatric acute respiratory failure and acute respiratory distress syndrome. Crit Care. 2019; 23(1):128. PMC: 6471952. DOI: 10.1186/s13054-019-2342-8. View

18.

Millar J, Fanning J, McDonald C, McAuley D, Fraser J . The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016; 20(1):387. PMC: 5125043. DOI: 10.1186/s13054-016-1570-4. View

19.

Goldstein L, Perez R, Yardley D, Han L, Reuben J, Gao H . A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Res. 2020; 22(1):4. PMC: 6954543. DOI: 10.1186/s13058-019-1243-8. View

20.

Piemonti L, Landoni G . COVID-19 and islet transplantation: Different twins. Am J Transplant. 2020; 20(11):2983-2988. PMC: 7272865. DOI: 10.1111/ajt.16001. View